A cost-effectiveness analysis of the application of nitric oxide versus oxygen gas for near-term newborns with respiratory failure: Results from a Canadian randomized clinical trial

Critical Care Medicine

Volumn 28, Issue 3, 2000, Pages 872-878

  Jacobs, Philip ^a,c   Finer, Neil N ^b   Robertson, Charlene M T ^a   Etches, Philip ^a   Hall, Edward M ^a   Saunders, L Duncan ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTE OF HEALTH ECONOMICS   (Canada)

Author keywords

Canada; Cost of illness; Cost savings; Cost benefit analysis; Costs and cost analysis; Extracorporeal membrane oxygenation; Infant diseases; Nitric oxide; Respiratory distress syndrome; Therapy

Indexed keywords

NITRIC OXIDE; OXYGEN;

CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; EXTRACORPOREAL OXYGENATION; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0034121329     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200003000-00043     Document Type: Review

References (40)

1. 1. Linde-Zwirble WT, Angus DC, Clermont G, et al: Diagnoses associated with the delivery of mechanical ventilation of the newborn. Pediatr Res 1997; 41:202A
2. 2. Khoshnood B, Kwang-sun L, Corpuz M, et al: Models for determining cost of care and length of stay in neonatal intensive care units. Int J Technol Assess Health Care 1996; 12:62-71
3. 3. Marshall PB, Halls H, James SL, et al: The cost of intensive and special care in the newborn. Med J Aust 1989; 150:568-572
4. 4. Mugford M, Piercy J, Chalmers I: Cost implications of different approaches to the prevention of respiratory distress syndrome. Arch Dis Child 1991; 66:757-764
5. 5. Newns B, Drummond MF, Durbin GM, et al: Costs and outcomes in a regional neonatal intensive care unit. Arch Dis Child 1984; 59:1064-1067
6. 6. Redmond CR, Loe WA, Bartlett RH, et al: Extracorporeal membrane oxygenation. In: Goldsmith J, Karetkin E (Eds). Assisted Ventilation of the Neonate. Second Edition. Philadelphia. Saunders, 1988, p 200-212
7. 7. Robertson CMT, Finer NN, Sauve RS, et al: Neurodevelopmental outcome after neonatal extracorporeal membrane oxygenation. CMAJ 1995; 152:1981-1988
8. 8. Bartlett RH, Toomasion J, Roloff D, et al: Extracorporeal membrane oxygenation (ECMO) in a neonatal respiratory failure: 100 cases. Ann Surg 1986; 204:236-244
9. 9. Schumaker RE, Roloff DW, Chapman R, et al: Extracorporeal membrane oxygenation in term newborns: A prospective cost-benefit analysis. ASAIO J 1993; 39:873-879
10. 10. Zuischenberger JB, Bartlett R: Extracorporeal circulation for respiratory or cardiac failure. Semin Thorac Cardiovasc Surg 1988; 2:320-331
11. 11. Stolar CJH, Snedecor SM, Bartlett RH: Extracorporeal membrane oxygenation and neonatal respiratory failure: Experience from the Extracorporeal Life Organization. J Pediatr Surg 1991; 26:563-571
12. 12. UK Collaborative ECMO Trial Group: UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. Lancet 1996; 348:75-82
13. 13. Bartlett RH, Roloff DW, Cornell RG, et al: Extracorporeal circulation in neonatal respiratory failure: a prospective randomized study. Pediatrics 1985; 76:479-487
14. 14. O'Rourke PP, Krone R, Vacanti J, et al: Extracorporeal membrane oxygenation and conventional medical therapy in neonates with persistent pulmonary hypertension of the newborn: A prospective randomized study. Pediatrics 1989; 84:957-63
15. 15. Howard S, Mugford M, Normand C, et al: A cost effectiveness analysis of neonatal ECHO using existing evidence. Int J Technol Assess Health Care 1996; 12:80-92
16. 16. Pearson DG, Short BL: An economic analysis of extracorporeal membrane oxygenation 1987; Intensive Care Med 2:116-120
17. 17. Finer NN, Etches PC, Kamstra B, et al: Inhaled nitric oxide in newborns referred for extracorporeal membrane oxygenation: dose response. J Pediatr 1994; 124:302-308
18. 18. Kinsella JP, Neish SR, Shaffer E, et al: Low dose inhalational nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. Lancet 1992; 340:819-820
19. 19. Neonatal Inhaled Nitric Oxide Study Group: Inhaled nitric oxide in the term and near term infant with hypoxic respiratory failure. N Engl J Med 1997; 336:597-604
20. 20. Neonatal Inhaled Nitric Oxide Study Group: Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics 1997; 99:838-845
21. 21. Sinclair JC: Economic evaluation of neonatal intensive care. Int J Technol Assess Health Care 1991; 2(Suppl.1):146-150
22. 22. Drummond MF, Stoddart GL, Torrance GW: Methods for the Economic Evaluation of Health Care Programmes. Toronto: Oxford University Press, 1987
23. 23. Canadian Coordinating Office for Health Technology Assessment: Guidelines for the Economic Evaluation of Pharmaceuticals: Canada. Second edition. Ottawa, Canadian Coordinating Office for Health Technology Assessment, 1998
24. 24. Canadian Coordinating Office for Health Technology Assessment: A Guidance Document for the Costing Process. Version 1. 0. Ottawa, Canadian Coordinating Office for Health Technology Assessment, 1996
25. 25. Elbourne D: The UK Collaborative ECMO Trial. Midwives Chron 1994; 107:312-316
26. 26. Roberts TE and the Extracorporeal Membrane Oxygenation Economics Working Group: Economic evaluation and randomised controlled trial of extracorporeal membrane oxygenation: UK collaborative trial. BMJ 1998; 317:911-915
27. 27. Efron B, Tibsharini R: An Introduction to the Bootstrap. New York, Chapman and Hall, 1993
28. 28. Chaudhary MA, Stearns SC: Estimating confidence intervals for cost-effectiveness ratios: An example from a randomized clinical trial. Stat Med 1996; 15:1447-1458
29. 29. O'Brien B, Drummond MF, Labelle RJ, et al: In search of power and significance: Issues in the design and analysis of stochastic cost effectiveness studies in health care. Med Care 1994; 32:150-163
30. 30. Polsky D, Click HA, Willke R, et al: Confidence intervals for cost-effectiveness ratios: A comparison of four methods. Health Econ 1997; 6:243-252
31. 31. Laupacis A, Feeny D, Detsky A, et al: How attractive does a technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146:473-481
32. 32. Hofkosh D, Thompson AE, Nozza RJ, et al: Ten years of extracorporeal membrane oxygenation: Neurodevelopmental mental outcome. Pediatrics 1991; 87:549-555
33. 33. Schumacher RE, Palmer TW, Roloff DW, et al: Follow-up of infants treated with extracorporeal membrane oxygenation for newborn respiratory failure. Pediatrics 1991; 87: 451-457
34. 34. Adolph V, Ekelund C, Smth C, et al: Developmental outcome of neonates treated with extracorporeal membrane oxygenation. J Pediatr 1991; 119:787-792
35. 35. Wildon SR, Landry SH, Zwischenberger JB: Prospective controlled study of developmental outcome in survivors of Extracorporeal Membrane Oxygenation: The first 24 months. Pediatrics 1994; 93:404-408
36. 36. Robertson CMT, Finer NN, Sauve RS, et al: Neurodevelopmental outcome after extracorporeal membrane oxygenation. CMAJ 1995; 152:1981-1988
37. 37. Cheung P-Y, Magathan-Haluschak M, Finer NN, et al: Sensorineural hearing loss in survivors of neonatal extracorporeal membrane oxygenation. Early Hum Dev 1996; 14:225-233
38. 38. Robertson CMT, Cheung P-Y, Magathan-Haluschak M, et al: High prevalence of sensorineural hearing loss among survivors ofneonatal congenital diaphragmatic hernia. Am J Otol 1998; 19:730-736
39. 39. McCormick MC, Bernbaum J, Eisenberg JM, et al: Costs incurred by parents of very low birth weight newborns after the initial neonatal hospitalization. Pediatrics 1991; 88: 533-541
40. 40. McLoughlin A, Hillier VF, Robinson R: Parental costs of neonatal visiting. Arch Dis Child 1993; 68:597-599